Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-02

Clinical Trial Update: Open-label Extension Study Of RN624 [Phase 2]

View source ↗

Summary

Open-label extension study update for RN624 in phase 2 in osteoarthritis and knee pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RN624

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, OA Knee Pain | Phase 2 | Status: COMPLETED | Results posted: 2021-02-02